Hangzhou Yili Pharmaceutical Co., Ltd. has completed a Series A financing round of nearly 400 million yuan, led by Huagai Capital, with Kangjun Capital as co-lead investor, and joint participation from Boyu Venture Capital, Delian Capital, Xincheng Fund, Haibang Investment, Bairui Capital, Shenzhen Angel, and Yuanyi Investment. Existing shareholders Shiyao Guofang Xiandao Fund, Huaige Capital, Xinneng Venture Capital, Longfeng Venture Capital, Hongsheng Capital, Beike Fund, and Honghou Investment continued to increase their investment.
According to public information, Yili Pharmaceutical was founded in 2024, with founder and CEO Dr. Yu Feng. The company focuses on integrated radiotherapeutics for tumors and neurological diseases, combining molecular targeting technology with radionuclide technology to simultaneously develop diagnostic and therapeutic radiopharmaceuticals. The company has previously completed multiple rounds of financing, with several target candidate molecules having completed lead compound discovery and in vitro and in vivo validation, and some projects are about to advance to IND filing.
Comments